|
|
News Breaks
|
February 10, 2010
|
| 06:17 EDT |  | BAYRY |
| theflyonthewall.com: | Bayer appeal rejected by Indian court, Times of India reports | | The Delhi high court has reportedly dismissed an appeal by German MNC Bayer (BAYRY), which was looking to link regulatory approval of generic medicines with their patent status. The judgment was made on an anti-cancer drug, as patent linkage is against public health interests. Reference Link :theflyonthewall.com |
|
|
News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 16:09 EDT |  | BAYRY |
| theflyonthewall.com: | Watson Pharmaceuticals confirms Beyaz patent challenge | | Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is a generic version of Bayer HealthCare Pharmaceuticals' (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception. :theflyonthewall.com |
| | 15:30 EDT | | BAYRY |
| | 14:11 EDT | | BAYRY |
| | 11:58 EDT |  | BAYRY |
|
|
January 30, 2012
|
| 07:29 EDT | | BAYRY |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information